Lung Cancer
Conference Coverage
Most community-based oncologists skip biomarker testing
Survey shows that 48% of community clinicians use biomarker testing to guide treatment decisions, compared with 73% of academic clinicians.
Latest News
FDA approves first oral drug for NSCLC with EGFR Exon 20 insertion
Mobocertinib is the first oral tyrosine kinase inhibitor for patients with metastatic non–small cell lung cancer who have an EGFR Exon 20...
News
Immunotherapy for cancer patients with poor PS needs a rethink
Patients should not receive immunotherapy just to reduce risk of side effects, doctor says.
Conference Coverage
COVID is especially dangerous for mesothelioma
Case review demonstrates a mortality rate of 57%.
Conference Coverage
Pandemic strategies to boost trial enrollment should stay
Conference Coverage
Air pollution – second leading cause of lung cancer
“As lung cancer professionals, we can mitigate the effects of air pollution on causing lung cancer by speaking out for clean energy standards.”
Article
Racial Disparities in Treatment and Survival for Early-Stage Non-Small Cell Lung Cancer: Is Equal Access Health Care System the Answer?
Article
Survival Analysis of Untreated Early-Stage Non-Small Cell Lung Cancer (NSCLC) in a Veteran Population
News
Pfizer recalls four more lots of smoking cessation drug Chantix
On July 2, the FDA reported that Pfizer had voluntarily recalled nine lots of the drug.
Latest News
One in three cancer articles on social media has wrong info
Physician says misleading information online may be harmful to patients.